<DOC>
	<DOCNO>NCT00655863</DOCNO>
	<brief_summary>The purpose study compare efficacy Alogliptin , daily ( QD ) , take pioglitazone postprandial lipid measure type 2 diabetes .</brief_summary>
	<brief_title>Efficacy Alogliptin With Pioglitazone Patients With Type 2 Diabetes .</brief_title>
	<detailed_description>SYR-322 ( alogliptin ) selective , orally available inhibitor dipeptidyl peptidase IV develop treatment type 2 diabetes mellitus . Dipeptidyl peptidase IV primary enzyme involve vivo degradation least 2 peptide hormone release response nutrient ingestion , namely glucagon-like peptide-1 glucose-dependent insulinotropic peptide . Pioglitazone HCl ( ACTOS® ) thiazolidinedione develop Takeda Chemical Industries , Ltd. ( Osaka , Japan ) . Pioglitazone HCl depend presence insulin mechanism action . This study assess effect alogliptin alogliptin coadministered pioglitazone HCl postprandial lipid lipoprotein metabolism participant type 2 diabetes . Individuals participate study require commit screen visit 6 additional visit study center . Study participation anticipate 20 week ( approximately 5 month ) . Multiple procedure occur visit may include fasting , blood collection , urine collection , physical examination electrocardiograms . At 3 visit meal serve must eat within 10 minute .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<criteria>Inclusion Criteria Diagnosis type 2 diabetes Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . Either fail treatment diet exercise 3 month prior Screening receive stable dose metformin , sulfonylurea , nateglinide , repaglinide 3 month prior Screening . Inadequate glycemic control define glycosylated hemoglobin concentration 6.5 9.0 % , inclusive . Fasting plasma glucose less 13.3 mmol per L. Fasting serum triglyceride level 1.7 5.0 mmol per L , inclusive . Has receive lipidlowering therapy within 3 month prior Screening stable statin and/or ezetimibe therapy ( drug dose ) least 3 month . Body mass index great 23 kg/m2 less 45 kg/m2 . If regular use , nonexcluded medication , must stable dose least 4 week prior Screening . Use need prescription medication overthecounter medication allow discretion investigator . Is Apolipoprotein E 3/3 Apolipoprotein E 3/4 phenotype positive prior baseline . Exclusion Criteria History type 1 diabetes . History drug abuse ( define illicit drug use ) history alcohol abuse ( define regular daily consumption 4 alcoholic drink per day ) within past 2 year . Diastolic blood pressure great 100 mm Hg systolic blood pressure great 160 mm Hg . History cancer , basal cell carcinoma , remission least 5 year prior first dose study medication . Hemoglobin le 120 g per L male less than100 g per L female . Alanine transaminase level great 2.5 time upper limit normal , active liver disease , jaundice . Serum creatinine level great 133 μmol per L. Fasting total cholesterol great 6.5 mmol per L. New York Heart Association heart failure Class ( IIV ) regardless therapy . History coronary angioplasty , coronary stent placement , coronary bypass surgery , myocardial infarction within 6 month prior Screening . History acute metabolic diabetic complication . History hemoglobinopathy may affect determination glycosylated hemoglobin . History infection human immunodeficiency virus . History diabetic gastro paresis . History gastric bypass surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Glucose Metabolism Disorder</keyword>
	<keyword>Dysmetabolic Syndrome</keyword>
	<keyword>Type II Diabetes</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Lipoatrophic ; Dyslipidemia</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>